Anthony Oro, MD, PhD

Eugene and Gloria Bauer Professor

Bio

Anthony E. Oro, M.D., Ph.D., is the Eugene and Gloria Bauer Professor of Dermatology, Associate Director of the Center for Definitive and Curative Medicine, and the co-director of the Child Health Research Institute. He is co-founder of the Program in Epithelial Biology, and an active member of the Institute for Stem Cell Biology and Regenerative Medicine, Children’s Health Research Institute, Bio-X, and the Program in Cancer Biology. His research interests encompass cancer genomics and tumor evolution, stem cell biology and hair/skin development and regeneration, and definitive molecular and cellular therapeutics. His clinical interests include hair biology, non-melanoma skin cancer, and stem cell-based therapies for genetic skin diseases.

Clinical Focus

Cancer > Cutaneous (Dermatologic) Oncology
Dermatology
Skin Cancer
Hair disorders
Genetic Skin Disease
Epidermolysis Bullosa
Therapeutic Reprograming
Therapeutic Reprogramming
Stem Cell
Regenerative Medicine

Academic Appointments

Professor, Dermatology
Member, Bio-X
Member, Institute for Stem Cell Biology and Regenerative Medicine
Member, Maternal & Child Health Research Institute (MCHRI)
Member, Stanford Cancer Institute
Member, Wu Tsai Neurosciences Institute

Administrative Appointments

Assoc Director, Center for Definitive and Curative Medicine (2016 - Present)
Co-Director, Child Health Research Institute (2017 - Present)

Professional Education

Medical Education: University of California San Diego School of Medicine (1993) CA
Residency: Stanford University Dermatology Residency (1997) CA
Internship: Stanford University Internal Medicine Residency (1994) CA
Board Certification: American Board of Dermatology, Dermatology (1998)

Contact

Academic oro@stanford.edu Tel: (650) 723-7843 Fax: (650) 723-8762

Administrative Contact Inna Gitman Admin Assistant innag@stanford.edu Tel: 650-736-7473

Clinical (Primary)

This is the primary clinic for this clinical provider. For additional clinical locations and information, please visit the link(s) listed below in the 'Additional Clinical Info' section.

Adult Dermatology Clinic 450 Broadway St Pavilion B MC 5334 Redwood City CA 94063 Tel: (650) 723-6316 Fax: (650) 721-3476

Additional Clinical Info

Current Research and Scholarly Interests

Our lab studies skin stem cells to understand mechanisms of tissue regeneration and carcinogenesis. We have a longstanding interest in the mechanisms of Sonic hedgehog (Shh) signaling in the hair follicle and n the pathogenesis of the most common human tumor, basal cell carcinoma (BCCs) of the skin. We have provided clinical evidence for the first hedgehog pathway inhibitor and are developing novel targets for next generation inhibitors that target the transcription factor Gli. We are studying the mechanisms of tumor evolution and the development of chemoresistance to targeted agents in both patients and mouse models using genomics and bioinformatic methods followed by functional validation.

We are also interested in the mechanisms of human skin development and early ectodermal differentiation and have developed in vitro human skin differentiation from embryonic stem cells. Using this system, we are exploring how early ectoderm commits to stratified epithelium. We have used our system, in collaboration with other labs at Stanford, to manufacture corrected human epidermal sheets from patient-specific iPS cells.

Clinical Trials

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study Not Recruiting
More
This was a multicenter, open-label extension study. Patients who received vismodegib (GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who continued to receive vismodegib at the time the parent study closed were eligible for continued treatment in this protocol.

Stanford is currently not accepting patients for this trial. For more information, please contact Shruthi Rangaraj, 6507217159.
Lead Sponsor
Stanford Investigators
View full details
Tofacitinib for the Treatment of Alopecia Areata and Its Variants Not Recruiting
More
The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants.

Stanford is currently not accepting patients for this trial. For more information, please contact Michelle Kim, .

Lead Sponsor
- Stanford University
Stanford Investigators
- Justin M Ko, MD, MBA
- Anthony Oro, MD, PhD
View full details
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma Not Recruiting
More
This was a Phase II, single-arm, two-cohort multicenter clinical trial evaluating the efficacy and safety of vismodegib (GDC-0449) in patients with advanced basal cell carcinoma. All patients received vismodegib until evidence of progression, intolerable toxicities most probably attributable to vismodegib, or withdrawal from the study.

Stanford is currently not accepting patients for this trial. For more information, please contact Katherine Connors, 6507217159.
Lead Sponsor
Stanford Investigators
View full details
A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma Not Recruiting
More
This is an open-label, non-comparative, multicenter, expanded access study of Vismodegib (GDC-0449) in patients with locally advanced basal cell carcinoma (BCC) or metastatic BCC (mBCC) who are otherwise without satisfactory treatment options.

Stanford is currently not accepting patients for this trial. For more information, please contact Shruthi Rangaraj, 6507217159.
Lead Sponsor
Stanford Investigators
View full details
Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa Recruiting
More
Recessive dystrophic epidermolysis bullosa (RDEB) is a disease caused by genetic mutations in the gene for type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening subjects with RDEB to evaluate characteristics of the subjects and their cells in order to develop new strategies of therapy and determine whether subjects could be candidates for treatment studies.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma Not Recruiting
More
This study assessed the efficacy and safety of oral treatment with two dose levels of LDE225 in patients with locally advanced or metastatic BCC.

Stanford is currently not accepting patients for this trial. For more information, please contact Shruthi Rangaraj, 6507217159.
Lead Sponsor
Stanford Investigators
- Anthony Oro, MD, PhD
View full details
Levocarnitine in Treating Patients With Vismodegib-Associated Muscle Spasms Not Recruiting
More
This randomized clinical trial studies levocarnitine in treating patients with vismodegib-associated muscle spasms. Levocarnitine may decrease muscle spasms caused by vismodegib.

Stanford is currently not accepting patients for this trial. For more information, please contact Anne Lynn Chang, 650-721-7151.

Lead Sponsor
- Stanford University
Stanford Investigators
- Anthony Oro, MD, PhD
View full details
A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies Not Recruiting
More
The primary objectives of the study are: - To determine the safety and the maximum tolerated dose (MTD) of IPI-926 - To examine the pharmacokinetic parameters of IPI-926 and its characterized major metabolite(s) - To recommend a dose and schedule of IPI-926 for subsequent studies

Stanford is currently not accepting patients for this trial. For more information, please contact Shruthi Rangaraj, 6507217159.
Lead Sponsor
Stanford Investigators
- Anthony Oro, MD, PhD
View full details
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma Not Recruiting
More
This pilot trial studies how well sonidegib and buparlisib work in treating patients with basal cell carcinoma that has spread to other places in the body. Sonidegib and buparlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Stanford is currently not accepting patients for this trial. For more information, please contact Anne Lynn Chang, 650-721-7151.
Lead Sponsor
Stanford Investigators
View full details
Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma Not Recruiting
More
This pilot clinical trial studies arsenic trioxide in treating patients with basal cell carcinoma. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stop them from dividing

Stanford is currently not accepting patients for this trial. For more information, please contact Irene Bailey-Healy, 408-892-7261.

Lead Sponsor
- Stanford University
Stanford Investigators
- Anthony Oro, MD, PhD
- A. Dimitrios Colevas, MD
View full details
A Study in Advanced Cancer Not Recruiting
More
The purpose of this study is to find a recommended dose level and schedule of dosing LY2940680 that can safely be taken by participants with advanced cancer. The study will also explore the changes in a cancer marker level in skin, hair follicles, buccal cells, and tumor cells. Finally, the study will help document any antitumor activity this drug may have.

Stanford is currently not accepting patients for this trial. For more information, please contact Anne Chang, 650-721-7151.
Lead Sponsor
Stanford Investigators
View full details
Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors Not Recruiting
More
This is a prospective single-center, open label, pilot study to investigate the safety and efficacy of LDE225 in patients with locally advanced or metastatic basal cell carcinoma. Primary Objectives: • To explore the effects of oral LDE225 on the Progression Free Survival (PFS) of individuals with locally advanced or metastatic BCC who have been previously treated with a non-LDE225 Smo inhibitor. Secondary Objectives: - To evaluate the effect of oral LDE225 on tumor tissue biomarkers of BCC activation (Gii 1, 2, Patched 1,2 and Ki67) in individuals which are non-na"ive to Smo inhibitors other than LDE225, at baseline and at end-of-treatment - To describe adverse effects of oral LDE225 in individuals with a history of non-LDE225 Smo inhibitor usage - To assess the overall survival rates of individuals with locally advanced BCC or metastatic BCC who have previously taken a non-LDE225 Smo inhibitor after treatment with LDE225

Stanford is currently not accepting patients for this trial. For more information, please contact Shruthi Rangaraj, 650-721-7159.
Lead Sponsor
Stanford Investigators
View full details
Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC) Not Recruiting
More
The purpose of this study is to learn about the effect of vismodegib on sporadic basal cell carcinoma (BCCs) prior to surgical removal.

Stanford is currently not accepting patients for this trial. For more information, please contact Irene Bailey, 650-721-7149.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
Topical Itraconazole in Treating Patients With Basal Cell Cancer Not Recruiting
More
This phase 0 trial studies how well itraconazole gel works in treating patients with basal cell cancer. Itraconazole gel may help to treat basal cell tumors in patients.

Stanford is currently not accepting patients for this trial. For more information, please contact Irene Bailey-Healy, 650-721-7149.
Lead Sponsor
Stanford Investigators
- Anthony Oro, MD, PhD
View full details

2023-24 Courses

Independent Studies
- Directed Reading in Cancer Biology
  CBIO 299 (Aut, Win, Spr, Sum)
- Directed Reading in Dermatology
  DERM 299 (Aut, Win, Spr, Sum)
- Early Clinical Experience in Dermatology
  DERM 280 (Aut, Win, Spr, Sum)
- Graduate Research
  CBIO 399 (Aut, Win, Spr, Sum)
- Graduate Research
  DERM 399 (Aut, Win, Spr, Sum)
- Graduate Research
  STEMREM 399 (Aut, Win, Spr, Sum)
- Medical Scholars Research
  DERM 370 (Aut, Win, Spr, Sum)
- Out-of-Department Advanced Research Laboratory in Bioengineering
  BIOE 191X (Aut, Win, Spr, Sum)
- Out-of-Department Graduate Research
  BIO 300X (Aut, Win, Spr, Sum)
- Out-of-Department Undergraduate Research
  BIO 199X (Aut, Win, Sum)
- Teaching in Cancer Biology
  CBIO 260 (Spr)
- Undergraduate Research
  DERM 199 (Aut, Win, Spr, Sum)

Stanford Advisees

Med Scholar Project Advisor
Candice Kim, Carmel McCullough, Mihir Shah
Doctoral Dissertation Reader (AC)
Derek Le, Kenisha Puckett, Xue Yang
Postdoctoral Faculty Sponsor
Zihao Deng, Anna Jussila, Egor Sedov, Ying Yang
Doctoral Dissertation Advisor (AC)
Franco Felix, Maria Gonzalez, Michelle Kinney, Yanzhe Li
Postdoctoral Research Mentor
Ying Yang

Graduate and Fellowship Programs

Bioengineering (Phd Program)
Biomedical Informatics (Phd Program)
Cancer Biology (Phd Program)
Dermatology (Fellowship Program)
Genetics (Phd Program)
Stem Cell Biology and Regenerative Medicine (Phd Program)

All Publications

Profiles With Related Publications

close
Sumaira Z. Aasi, MD

Clinical Professor, Dermatology
Clinical Focus
Cancer > Cutaneous (Dermatologic) Oncology, Dermatologic Surgery, Mohs Micrographic Surgery, Melanoma and Skin Cancer, Skin oncology in transplant patients, Laser Surgery, Dermatology
Research Interests
High risk squamous cell carcinoma; frozen histopathology; reconstructive surgery.

119 Total Publications
close
Jeffrey Axelrod

Professor of Pathology
Research Interests
Genetic and cell biological analyses of signals controlling cell polarity and morphogenesis. Frizzled signaling and cytoskeletal organization.

95 Total Publications
close
Anne Lynn S. Chang, MD

Professor of Dermatology
Clinical Focus
Cancer > Cutaneous (Dermatologic) Oncology, Dermatology, Skin Cancer, Geriatric dermatology, basal cell carcinoma, squamous cell carcinoma, immunotherapy for non-melanoma skin cancer, clinical trials, non-melanoma skin cancer, skin longevity, acne rosacea, rosacea
Research Interests
I have two main research interests:
1) to better understand and treat patients with aggressive basal and squamous cell carcinomas
2) to better understand the genetic and epigenetic mechanisms of healthy human skin aging and to translate these insights into better care of skin diseases enriched in older patients particularly skin cancer and rosacea

291 Total Publications
close
James K. Chen

Jauch Professor and Professor of Chemical and Systems Biology, of Developmental Biology and of Chemistry
Research Interests
Our laboratory combines chemistry and developmental biology to investigate the molecular events that regulate embryonic patterning, tissue regeneration, and tumorigenesis. We are currently using genetic and small-molecule approaches to study the molecular mechanisms of Hedgehog signaling, and we are developing chemical technologies to perturb and observe the genetic programs that underlie vertebrate development.

90 Total Publications
close
Gerald Crabtree

David Korn, MD, Professor of Pathology and Professor of Developmental Biology
Research Interests
Chromatin regulation and its roles in human cancer and the development of the nervous system. Engineering new methods for studying and controlling chromatin and epigenetic regulation in living cells.

262 Total Publications
close
Peter K. Jackson

Professor of Microbiology and Immunology (Baxter Labs) and of Pathology
Research Interests
Cell cycle and cyclin control of DNA replication .

180 Total Publications
close
Paul A. Khavari, MD, PhD

Carl J. Herzog Professor of Dermatology in the School of Medicine
Clinical Focus
Cancer > Cutaneous (Dermatologic) Oncology, Dermatology, General Dermatology
Research Interests
We work in epithelial tissue as a model system to study stem cell biology, cancer and new molecular therapeutics. Epithelia cover external and internal body surfaces and undergo constant self-renewal while responding to diverse environmental stimuli. Epithelial homeostasis precisely balances stem cell-sustained proliferation and differentiation-associated cell death, a balance which is lost in many human diseases, including cancer, 90% of which arise in epithelial tissues.

222 Total Publications
close
Seung K. Kim M.D., Ph.D.

KM Mulberry Professor, Professor of Developmental Biology, of Medicine (Endocrinology) and, by courtesy, of Pediatrics (Endocrinology)
Research Interests
We study the development of pancreatic islet cells using molecular, embryologic and genetic methods in several model systems, including mice, pigs, human pancreas, embryonic stem cells, and Drosophila. Our work suggests that critical factors required for islet development are also needed to maintain essential functions of the mature islet. These approaches have informed efforts to generate replacement islets from renewable sources for diabetes.

89 Total Publications
close
Mark Krasnow

Paul and Mildred Berg Professor
Research Interests
- Lung development and stem cells
- Neural circuits of breathing and speaking
- Lung diseases including lung cancer
- New genetic model organism for biology, behavior, health and conservation

121 Total Publications
close
Alfred Lane

Professor of Dermatology and of Pediatrics at the Stanford University Medical Center, Emeritus
Research Interests
Developing gene therapy for genetic skin diseases is my major focus. Prior to that, we are developing methods to give effective and efficient care to infants with rare and disabling genetic skin diseases including epidermolysis bullosa and ichthyosis as well as infants and children with unusual and difficult to manage vascular malformations. I am also interested in clinical studies within the NICU protecting premature infants skin and clinical studies in children with common skin diseases.

73 Total Publications
close
Kif Liakath-Ali

Instructor, Molecular & Cellular Physiology

29 Total Publications
close
M. Peter Marinkovich, MD

Associate Professor of Dermatology
Clinical Focus
Cancer > Cutaneous (Dermatologic) Oncology, Epidermolysis Bullosa, Autoimmune Blistering Diseases, Pemphigus, Pemphigoid, Linear IgA Disease, Dermatitis Herpetiformis, Herpes Gestations, Clinical and Laboratory Dermatological Immunology
Research Interests
The Marinkovich lab studies the function of epithelial extracellular matrix molecules, including integrins, collagens and laminins in epithelial development and carcinoma progression. We apply our discoveries in this area towards development of molecular therapies for carcinomas, hair disease and inherited epithelial adhesive disorders.

250 Total Publications